Workflow
杭州天目山药业股份有限公司 2025年第一季度报告

Core Viewpoint - The company has announced a share buyback plan by a major shareholder, indicating confidence in the company's future development and value [5]. Financial Data - The financial report for the first quarter of 2025 is unaudited, with no significant changes in accounting data or financial indicators reported [3][6]. - The company reported a total shareholding increase of 1,114,100 shares by the major shareholder, representing 0.91% of the total share capital, with a total investment of approximately 1,002.69 million RMB [5]. Shareholder Information - The major shareholder, Yuanjia Medical, plans to increase its stake in the company by investing between 10 million and 20 million RMB within six months starting from August 24, 2024 [5]. - After the completion of the buyback plan, Yuanjia Medical will hold 16,160,000 shares, accounting for 13.27% of the total share capital [5].